ovalbumin and Lung-Diseases--Interstitial

Childhood trauma may contribute to poorer premorbid social and academic adjustment which may be a risk factor for schizophrenia.. We explored the relationship between premorbid adjustment and childhood trauma, timing of childhood trauma's moderating role as well as the association of clinical and treatment-related confounders with premorbid adjustment.. Type of childhood trauma was assessed with the Childhood Trauma Questionnaire, short-form and premorbid adjustment using the Premorbid Adjustment Scale. Timing of childhood trauma was assessed using the Life Events Checklist and life events timeline. Linear regression analyses were used to assess the moderating effect of timing of childhood trauma. Clinical and treatment-related confounders were entered into sequential hierarchical regression models to identify independent predictors of premorbid adjustment across key life stages.. Childhood physical neglect was associated with poorer premorbid academic functioning during childhood and early adolescence, and poorer premorbid social functioning during early and late adolescence. By hierarchical regression modelling (. In patients with FES, childhood physical neglect may contribute to poorer premorbid social functioning during early adolescence. This may provide us with an opportunity to identify and treat at-risk individuals earlier.. Utilization of pharmacy services including telehealth, may allow clinical pharmacists to collaboratively provide remote services without jeopardizing patient outcomes. Larger studies are needed to confirm these findings, and display the long-term impact and satisfaction of these services.. Treatment of Staphylococcus aureus IE in IDUs on methadone treatment requires the use of high daptomycin daily doses in order to achieve satisfactory pharmacodynamic parameters. Close monitoring of the daptomycin plasma concentration is suggested.

Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Area Under Curve; Atherosclerosis; B7-H1 Antigen; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Calgranulin B; Cause of Death; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; COVID-19; COVID-19 Vaccines; CRISPR-Cas Systems; Daptomycin; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endocarditis, Bacterial; Enzyme Inhibitors; Extracellular Matrix; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Gene Targeting; Glioblastoma; Half-Life; Health Status; Heterocyclic Compounds, 1-Ring; Hospital Mortality; Humans; Interleukin-6; L-Lactate Dehydrogenase; Lung; Lung Diseases, Interstitial; Male; Matrix Metalloproteinase 13; Methadone; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Microglia; Middle Aged; Neuroendocrine Tumors; Octreotide; Opiate Substitution Treatment; Ovalbumin; Oxygen; Oxygen Inhalation Therapy; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Partial Pressure; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Quality of Life; Radiotherapy Dosage; Radiotherapy, Conformal; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Staphylococcal Infections; Staphylococcus aureus; Surveys and Questionnaires; Survival Rate; Sweden; Temozolomide; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Tumor-Associated Macrophages; Young Adult

In this era of immune checkpoint inhibitors, inflammatory adverse events of anti-cancer therapies continue to pose a major challenge. Glucocorticoids, as the mainstay, were limited by serious side effects. Glucocorticoids induce myeloid-derived suppressor cells (MDSCs), and lactoferrin-induced polymorphonuclear MDSCs (PMN-MDSCs) were shown to relieve inflammatory conditions. Combined treatment with dexamethasone (DXM) and lactoferrin increased the generation of PMN-MDSCs in vitro (DXM/lactoferrin PMN-MDSCs) compared to DXM or lactoferrin treatment alone. DXM/lactoferrin PMN-MDSCs were distinct from tumor PMN-MDSCs in vivo with regard to gene expression profiles. DXM upregulated the myeloid cell response to lactoferrin by inducing the lactoferrin receptor Lrp1. DXM/lactoferrin PMN-MDSCs presented anti-bacterial capability, increased PGE2 production, increased survival capability, and decreased tumor tissue homing. Transfer of DXM/lactoferrin PMN-MDSCs relieved cisplatin-induced acute kidney failure, bleomycin-induced interstitial pneumonia, and allergic pneumonitis effectively without promoting tumor development. Our study shows that DXM/lactoferrin PMN-MDSCs are a promising cell therapy for inflammatory adverse events of anti-cancer therapies.

Topics: Acute Kidney Injury; Adoptive Transfer; Animals; Anti-Inflammatory Agents; Bleomycin; Cell Line, Tumor; Cisplatin; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Lactoferrin; Lung Diseases, Interstitial; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Ovalbumin; Phenotype; Pneumonia